Oxcia contracts Patheon for manufacturing and further strengthens the organization
Oxcia, a pioneer in oxidative DNA damage and DNA Damage Response (DDR) with a focus on developing new safe treatments for cancer and inflammation, has contracted Patheon for upscaling and production of OXC-101 substance and tablets for the upcoming Phase 2 clinical trials. OXC-101 is Oxcia's first-in-class anticancer drug candidate, currently in phase 1 studies in patients with advanced solid cancers or blood cancers. Patheon is part of the global ThermoFisher Scientific Group and is a leading contract manufacturer with production in several countries. Oxcia continues to